Evidence map›Paper›PMID 34788313›Full record

ArticlePloS one2021

Cell-morphodynamic phenotype classification with application to cancer metastasis using cell magnetorotation and machine-learning.

Remy Elbez, Jeff Folz, Alan McLean, Hernan Roca, Joseph M Labuz, Kenneth J Pienta, Shuichi Takayama, Raoul Kopelman

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Quantitative cell imaging approaches to metastatic state profiling.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Remy ElbezApplied Physics Program, University of Michigan, Ann Arbor, Michigan, United States of America.
Jeff FolzBiophysics Program, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID 0000-0002-4823-3343
Alan McLeanDepartment of Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America.
Hernan RocaDepartment of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America.
Joseph M LabuzDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America.
Kenneth J PientaDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Shuichi TakayamaDepartment of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Raoul KopelmanApplied Physics Program, University of Michigan, Ann Arbor, Michigan, United States of America.

Funding

Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
Microfluidics in Biomedical Sciences Training ProgramT32EB005582 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, XUDONG · 2005 to 2020
$3.9M
Personalized Cancer Therapy Guided by Photoacoustic Chemical Imaging (PACI) of Tumor Microenvironment (TME)R01CA250499 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KLEER, CELINA G, WANG, XUEDING · 2020 to 2025
$3.1M
Photonic Nanosonophores for Functional and Structural ImagingR01CA186769 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOPELMAN, RAOUL, WANG, XUEDING · 2014 to 2018
$1.6M
Microfluidic Models of Metastatic CancerR01CA136829 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUKER, GARY D · 2009 to 2013
$1.5M
Magnetorotation: a Rapid Assay for Single Cell Drug Sensitivity of Cancer CellsR21CA160157 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOPELMAN, RAOUL · 2011 to 2012
$276k
NCI NIH HHS R01 CA136829NCI NIH HHS R01 CA186769NCI NIH HHS R01 CA250499NCI NIH HHS R21 CA160157NIBIB NIH HHS T32 EB005582NIDCR NIH HHS T32 DE007057
6 · The paper itself

Abstract

We define cell morphodynamics as the cell's time dependent morphology. It could be called the cell's shape shifting ability. To measure it we use a biomarker free, dynamic histology method, which is based on multiplexed Cell Magneto-Rotation and Machine Learning. We note that standard studies looking at cells immobilized on microscope slides cannot reveal their shape shifting, no more than pinned butterfly collections can reveal their flight patterns. Using cell magnetorotation, with the aid of cell embedded magnetic nanoparticles, our method allows each cell to move freely in 3 dimensions, with a rapid following of cell deformations in all 3-dimensions, so as to identify and classify a cell by its dynamic morphology. Using object recognition and machine learning algorithms, we continuously measure the real-time shape dynamics of each cell, where from we successfully resolve the inherent broad heterogeneity of the morphological phenotypes found in a given cancer cell population. In three illustrative experiments we have achieved clustering, differentiation, and identification of cells from (A) two distinct cell lines, (B) cells having gone through the epithelial-to-mesenchymal transition, and (C) cells differing only by their motility. This microfluidic method may enable a fast screening and identification of invasive cells, e.g., metastatic cancer cells, even in the absence of biomarkers, thus providing a rapid diagnostics and assessment protocol for effective personalized cancer therapy.

Indexed as

Epithelial-Mesenchymal TransitionMachine LearningNeoplasm MetastasisPhenotypeCell Line, TumorCell ShapeHumans

Identifiers

PMID34788313
PMCPMC8598033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.